Literature DB >> 24619277

Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage.

Jean-Claude Baron1, Karim Farid2, Eamon Dolan3, Guillaume Turc4, Siva T Marrapu5, Eoin O'Brien3, Franklin I Aigbirhio6, Tim D Fryer6, David K Menon7, Elizabeth A Warburton3, Young T Hong6.   

Abstract

By detecting β-amyloid (Aβ) in the wall of cortical arterioles, amyloid positron emission tomography (PET) imaging might help diagnose cerebral amyloid angiopathy (CAA) in patients with lobar intracerebral hemorrhage (l-ICH). No previous study has directly assessed the diagnostic value of (11)C-Pittsburgh compound B (PiB) PET in probable CAA-related l-ICH against healthy controls (HCs). (11)C-PiB-PET and magnetic resonance imaging (MRI) including T2* were obtained in 11 nondemented patients fulfilling the Boston criteria for probable CAA-related symptomatic l-ICH (sl-ICH) and 20 HCs without cognitive complaints or impairment. After optimal spatial normalization, cerebral spinal fluid (CSF)-corrected PiB distribution volume ratios (DVRs) were obtained. There was no significant difference in whole cortex or regional DVRs between CAA patients and age-matched HCs. The whole cortex DVR was above the 95% confidence limit in 4/9 HCs and 10/11 CAA patients (sensitivity=91%, specificity=55%). Region/frontal or occipital ratios did not have better discriminative value. Similar but less accurate results were found using visual analysis. In patients with sl-ICH, (11)C-PiB-PET has low specificity for CAA due to the frequent occurrence of high (11)C-PiB uptake in the healthy elderly reflecting incipient Alzheimer's disease (AD), which might also be present in suspected CAA. However, a negative PiB scan rules out CAA with excellent sensitivity, which has clinical implications for prognostication and selection of candidates for drug trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619277      PMCID: PMC4013776          DOI: 10.1038/jcbfm.2014.43

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  38 in total

1.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

Authors:  Sally Schroeter; Karen Khan; Robin Barbour; Minhtam Doan; Ming Chen; Terry Guido; Davinder Gill; Guriqbal Basi; Dale Schenk; Peter Seubert; Dora Games
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

4.  The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease.

Authors:  E Kövari; F R Herrmann; P R Hof; C Bouras
Journal:  Neuropathol Appl Neurobiol       Date:  2013-08       Impact factor: 8.090

Review 5.  Cerebral amyloid angiopathy. A critical review.

Authors:  H V Vinters
Journal:  Stroke       Date:  1987 Mar-Apr       Impact factor: 7.914

6.  Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease.

Authors:  P A Yates; R Sirisriro; V L Villemagne; S Farquharson; C L Masters; C C Rowe
Journal:  Neurology       Date:  2011-06-22       Impact factor: 9.910

7.  Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy.

Authors:  J Linn; A Halpin; P Demaerel; J Ruhland; A D Giese; M Dichgans; M A van Buchem; H Bruckmann; S M Greenberg
Journal:  Neurology       Date:  2010-04-27       Impact factor: 9.910

8.  Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility.

Authors:  Jennifer Landt; J Carlos D'Abrera; Anthony J Holland; Franklin I Aigbirhio; Tim D Fryer; Roberto Canales; Young T Hong; David K Menon; Jean-Claude Baron; Shahid H Zaman
Journal:  Arch Neurol       Date:  2011-03-14

9.  Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage.

Authors:  John V Ly; Christopher C Rowe; Victor L Villemagne; Jorge A Zavala; Henry Ma; Graeme O'Keefe; Sylvia J Gong; Rico Gunawan; Leonid Churilov; Tim Saunder; Uwe Ackerman; Henri Tochon-Danguy; Geoffrey A Donnan
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

10.  Distribution volume ratios without blood sampling from graphical analysis of PET data.

Authors:  J Logan; J S Fowler; N D Volkow; G J Wang; Y S Ding; D L Alexoff
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

View more
  25 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers.

Authors:  Hyemin Jang; Young Kyoung Jang; Hee Jin Kim; David John Werring; Jin San Lee; Yeong Sim Choe; Seongbeom Park; Juyeon Lee; Ko Woon Kim; Yeshin Kim; Soo Hyun Cho; Si Eun Kim; Seung Joo Kim; Andreas Charidimou; Duk L Na; Sang Won Seo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

3.  Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice.

Authors:  Ugo Paolo Guerra; Flavio Mariano Nobili; Alessandro Padovani; Daniela Perani; Alberto Pupi; Sandro Sorbi; Marco Trabucchi
Journal:  Neurol Sci       Date:  2015-06       Impact factor: 3.307

Review 4.  Emerging concepts in sporadic cerebral amyloid angiopathy.

Authors:  Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

Review 5.  Monogenic causes of stroke: now and the future.

Authors:  Rhea Y Y Tan; Hugh S Markus
Journal:  J Neurol       Date:  2015-06-03       Impact factor: 4.849

Review 6.  Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria.

Authors:  Steven M Greenberg; Andreas Charidimou
Journal:  Stroke       Date:  2018-01-15       Impact factor: 7.914

7.  Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation.

Authors:  Solène Ronsin; Gianluca Deiana; Ana Filipa Geraldo; Françoise Durand-Dubief; Laure Thomas-Maisonneuve; Maïté Formaglio; Virginie Desestret; David Meyronet; Norbert Nighoghossian; Yves Berthezène; Jérôme Honnorat; François Ducray
Journal:  Neurology       Date:  2016-02-05       Impact factor: 9.910

8.  Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal.

Authors:  Stuart J McCarter; Timothy G Lesnick; Val Lowe; Michelle M Mielke; Eleni Constantopoulos; Alejandro A Rabinstein; Scott A Przybelski; Hugo Botha; David T Jones; Vijay K Ramanan; Clifford R Jack; Ronald C Petersen; David Knopman; Bradley F Boeve; Melissa E Murray; Dennis W Dickson; Prashanthi Vemuri; Kejal Kantarci; R Ross Reichard; Jonathan Graff-Radford
Journal:  Neurology       Date:  2021-09-09       Impact factor: 9.910

Review 9.  Neuroimaging in aging and neurologic diseases.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Handb Clin Neurol       Date:  2019

10.  Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study.

Authors:  M Edip Gurol; J Alex Becker; Panagiotis Fotiadis; Grace Riley; Kristin Schwab; Keith A Johnson; Steven M Greenberg
Journal:  Neurology       Date:  2016-09-07       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.